<DOC>
	<DOCNO>NCT02471118</DOCNO>
	<brief_summary>This Canadian randomize , double-blind , placebo-controlled , multicenter study design evaluate clinical efficacy safety adalimumab versus placebo use treat subject diagnosis osteoarthritis knee , clinical feature inflammation , whose pain persist despite receive maximum tolerated dos conventional therapy .</brief_summary>
	<brief_title>Osteoarthritis Knee , Inflammation , Effect Adalimumab ( OKINADA )</brief_title>
	<detailed_description>This Canadian randomize , double-blind , placebo-controlled , multicenter study design evaluate clinical efficacy safety adalimumab versus placebo use treat subject diagnosis osteoarthritis knee , clinical feature inflammation , whose pain persist despite receive maximum tolerated dos conventional therapy . A total 130 subject enter study . Subjects randomize ( 1:1 ) baseline receive either adalimumab 40 mg every week placebo 16 week . The study drug self-administered via subcutaneous injection . Efficacy assess week 16 safety study drug monitor throughout study . At week 16 subject begin receive open label adalimumab 40 mg every week .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . ≥ 40 year age 2 . If female , subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential practicing method birth control : 3 . If female childbearing potential , serum pregnancy result must negative Screening 4 . Has diagnosis OA index knee accord ACR criterion , include radiological evidence OA ( KellgrenLawrence grade 2 3 ) . 5 . Has continual pain least 6 month prior Screening Visit , include pain persist despite conventional treatment , define one follow medication take daily one precede 6 month : acetaminophen ( 2 4 gram per day , maximum , tolerate recommend dose NSAID , acetaminophen/codeine combination ( i.e . Tylenol No . 2 , 3 , 4 take least 3 time daily ) . 6 . Has daily knee pain 4 week prior Screening Visit . 7 . Has pain score ≥ 4 ( 010 NRS ) index ( symptomatic ) knee Screening Baseline . 8 . If subject take Analgesic/NSAIDs , Analgesic/NSAIDs stable 14 day prior Baseline visit . 9 . Has clinical evidence knee effusion index ( symptomatic ) knee Screening Baseline . 10 . Able willing selfadminister SC injection available qualified person ( ) administer SC injection . 11 . Has voluntarily sign date approve informed consent form prior studyspecific procedure . 1 . Has history allergic reaction significant sensitivity constituent adalimumab . 2 . Has bone articular disease ( antecedent and/or current sign ) chondrocalcinosis , Paget 's disease ipsilateral limb target knee , rheumatoid arthritis , aseptic osteonecrosis , gout , septic arthritis , ochronosis , acromegaly , haemochromatosis , Wilson 's disease , osteochondromatosis , seronegative spondyloarthropathy , mixed connective tissue disease , collagen vascular disease , psoriasis , inflammatory bowel disease . 3 . Is upper tertile age raceadjusted norm body mass index ( BMI ) . 4 . Planned/anticipated surgery index knee study period . 5 . Already schedule surgery time study within 70 day end treatment . 6 . Prior arthroscopic open surgery index knee within 12 month Baseline . 7 . Has history cancer lymphoproliferative disease : Successfully completely treated cervical dysplasia , recurrence within last five year , Basal Squamous Cell Carcinoma adequately treat excised . 8 . Has prior treatment intravenous ( IV ) immunoglobulin investigational agent within 30 day 5 halflives agent Baseline , whichever longer . 9 . History neurologic symptom suggestive central nervous system ( CNS ) demyelinate disease ( e.g . multiple sclerosis ) . 10 . History uncontrolled diabetes , unstable ischemic heart disease , active congestive heart failure , New York Heart Association ( NHYA ) III , IV , inflammatory bowel disease , active peptic ulcer disease , recent stroke ( within 12 week Screening ) , condition , opinion investigator , would put patient risk participate study . 11 . Has concurrent local systemic infection would preclude use adalimumab . 12 . Has persistent severe infection ( ) require hospitalization treatment IV antibiotic within 30 day , oral antibiotic within 14 day , prior Baseline . 13 . History active tuberculosis listeriosis , infection suggestive significant profound immunosuppression , Pneumocystis carinii , aspergillosis systemic protozoal fungal infection . 14 . Has latent TB ( positive purify protein derivative ( PPD ) skin test , twostep PPD applicable , chest Xray indicative TB ) risk factor activation latent TB , e.g . previous exposure TB , initiate TB prophylaxis prior first adalimumab treatment . 15 . Will exclude CXR find change indicative old heal tuberculous lesion ( e.g . calcified nodule , fibrotic scar , apical basilar pleural thicken etc. ) . 16 . Has positive serology Hepatitis B Hepatitis C indicate active infection . 17 . Has history positive HIV status . 18 . Currently take likely begin antiretroviral therapy time course study . 19 . Female subject pregnant breastfeeding . 20 . Has history clinically significant drug alcohol abuse last year , prior Screening . 21 . Subject , opinion principal investigator , unlikely comply study protocol unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Inflammatory Type</keyword>
</DOC>